MedTrace Logo

CAR T Cell Immunotherapy for Pancreatic Cancer

NCT03323944 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-01-30

No results posted yet for this study

Summary

Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma

Conditions

Interventions

BIOLOGICAL

huCART-meso cells

Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Sponsors & Collaborators

Principal Investigators

  • Mark O'Hara, MD · Assistant Professor of Medicine, Penn Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-15
Primary Completion
2025-02-20
Completion
2025-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03323944 on ClinicalTrials.gov